Loading…
Grace Therapeutics, Inc. is projected to rise to $2.28 by 2027, a +9% move from its current price of $2.08. GRCE is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $2.03 | $2.08 | $2.13 | +0.05% |
| Aug 6 | $2.01 | $2.08 | $2.16 | +0.10% |
| Aug 7 | $1.99 | $2.08 | $2.18 | +0.14% |
| Aug 8 | $1.98 | $2.08 | $2.19 | +0.19% |
| Aug 9 | $1.97 | $2.08 | $2.21 | +0.24% |
| Aug 10 | $1.96 | $2.09 | $2.22 | +0.29% |
| Aug 11 | $1.95 | $2.09 | $2.23 | +0.34% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.95 | $2.09 | $2.23 | +0.34% |
| Week 2 | $1.90 | $2.09 | $2.30 | +0.67% |
| Week 3 | $1.87 | $2.10 | $2.36 | +1.01% |
| Week 4 | $1.84 | $2.11 | $2.41 | +1.35% |
| Week 5 | $1.82 | $2.12 | $2.46 | +1.69% |
| Week 6 | $1.80 | $2.12 | $2.50 | +2.03% |
| Week 7 | $1.78 | $2.13 | $2.54 | +2.37% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Grace Therapeutics, Inc. is a healthcare company focused on the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. Its lead product candidate is GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage.
The company also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangionectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN).
Grace Therapeutics, Inc. was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Grace Therapeutics, Inc. trades under the GRCE ticker. The current price is $2.08 and the company has a market cap of $33.85M. The stock is ranked 4703 by market capitalization, placing it among smaller-cap healthcare names.
Looking ahead, the multi-year forecast shows a bullish evolution for the stock’s average price, with the 2026 avg price projected at $2.08 and rising to $3.16 by 2030 and $15.12 by 2050, while max prices reach $4.57 in 2030 and $27.79 by 2050. The forecast also outlines substantial gains in ROI over time, signaling upside potential but also highlighting the inherent uncertainty of long-range estimates.
A major floor 15.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.5% away) — a key level to hold.
The nearest ceiling, 21.6% above — a clean break opens room to run.
A major ceiling 146.6% above — clearing it would confirm fresh momentum.
Key GRCE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GRCE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.16 | Sell | $2.15 | Sell |
| MA 10 | $2.27 | Sell | $2.23 | Sell |
| MA 20 | $2.37 | Sell | $2.30 | Sell |
| MA 50 | $2.35 | Sell | $2.44 | Sell |
| MA 100 | $2.94 | Sell | $2.72 | Sell |
| MA 200 | $3.20 | Sell | $2.97 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 30.55 | Neutral |
| Stoch RSI (14) | 4.28 | Buy |
| CCI (20) | -173.27 | Sell |
| Williams %R (14) | -97.50 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | -14.40 | Sell |
| Bollinger %B (20,2) | -0.02 | Buy |
| Stochastic %K (14) | 2.50 | Buy |
| TRIX (15) | -0.12 | Sell |
| Awesome (5,34) | -0.18 | Sell |
| Ultimate (7,14,28) | 13.22 | Buy |
| Momentum (10) | -0.39 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 2.03 | Buy |
| ADX (14) | 16.25 | Neutral |
| ATR (14) | 0.05 | Info |
The 30-day technical picture is neutral with RSI(14) at 30. The stock trades below the 50-day simple moving average (SMA50) of $2.35 and well below the 200-day simple moving average (SMA200) of $3.20.
Support is identified at $2.08 and resistance at $2.53, with a 30-day price range spanning $1.74 to $2.48. This setup indicates a balancing point around the current price, with potential pressure toward the resistance level if buying interest strengthens.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.07 | $2.08 | $2.85 | 0% | Neutral | |
| $1.83 | $2.28 | $2.99 | +9% | Neutral | |
| $2.00 | $2.56 | $3.49 | +23% | Bullish | |
| $2.12 | $2.77 | $3.87 | +33% | Bullish | |
| $2.39 | $3.18 | $4.55 | +53% | Bullish | |
| $2.87 | $3.88 | $5.67 | +87% | Bullish | |
| $3.02 | $4.16 | $6.18 | +100% | Bullish | |
| $3.21 | $4.48 | $6.77 | +115% | Bullish | |
| $3.28 | $4.64 | $7.12 | +123% | Bullish | |
| $3.25 | $4.66 | $7.25 | +124% | Bullish | |
| $4.75 | $7.25 | $11.97 | +249% | Bullish | |
| $8.99 | $15.22 | $27.36 | +632% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.07 | $2.08 | $2.58 | +0.00% |
| September 2026 | $1.84 | $2.17 | $2.63 | +4.37% |
| October 2026 | $1.83 | $2.17 | $2.66 | +0.09% |
| November 2026 | $1.89 | $2.25 | $2.78 | +3.57% |
| December 2026 | $1.91 | $2.30 | $2.85 | +2.01% |
Click any year to see its month-by-month GRCE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, GRCE could reach as high as $2.85, with a base case around $2.08 and support toward $2.07 — roughly 0% from $2.08. Price action looks broadly range-bound.
Expect GRCE to range from $1.83 to $2.99 through 2027. The $2.28 average target implies a +9% move from current prices. That is up +9% on the projected 2026 average. A consolidation phase looks the most probable path here.
The GRCE price prediction for 2028 points to an average of $2.56 (low $2.00, high $3.49) — a potential gain of +23% on today's $2.08. Momentum favours further upside here.
In 2029, GRCE is projected to trade between $2.12 and $3.87, averaging $2.77 — a potential gain of +33% from today's $2.08. That is up +8% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Grace Therapeutics, Inc.'s 2030 outlook centres on $3.18, within a $2.39 to $4.55 range. That is up +15% on the projected 2029 average. That marks a +53% change versus current levels. Momentum favours further upside here.
By 2031, GRCE could reach as high as $5.67, with a base case around $3.88 and support toward $2.87 — roughly +87% from $2.08. Buyers look set to stay in control over this stretch.
Expect GRCE to range from $3.02 to $6.18 through 2032. The $4.16 average target implies a +100% move from current prices. That is up +7% on the projected 2031 average. Momentum favours further upside here.
The GRCE price prediction for 2033 points to an average of $4.48 (low $3.21, high $6.77) — a potential gain of +115% on today's $2.08. Buyers look set to stay in control over this stretch.
In 2034, GRCE is projected to trade between $3.28 and $7.12, averaging $4.64 — a potential gain of +123% from today's $2.08. That is up +4% on the projected 2033 average. Momentum favours further upside here.
Grace Therapeutics, Inc.'s 2035 outlook centres on $4.66, within a $3.25 to $7.25 range. That is up 0% on the projected 2034 average. That marks a +124% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, GRCE could reach as high as $11.97, with a base case around $7.25 and support toward $4.75 — roughly +249% from $2.08. Momentum favours further upside here.
Expect GRCE to range from $8.99 to $27.36 through 2050. The $15.22 average target implies a +632% move from current prices. That is up +110% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in GRCE today (≈ 480.769231 GRCE) could be worth
$7,315.35
+$6,315.35 (+632%) by 2050 · US Dollar
Based on the average projected GRCE price of $15.22 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GRCEwould be worth at today's price.
$1,000 invested in GRCE on Jul 31, 2025 (≈ 346.020749 GRCE) would be worth
$719.72
-$280.28 (-28.0%) today · 0.72× · US Dollar
Based on a GRCE entry price of $2.89 vs. today's $2.08.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.33 | $892.7 | -10.7% |
| 1 month ago | $2.24 | $928.57 | -7.1% |
| 3 months ago | $2.34 | $888.89 | -11.1% |
| 6 months ago | $3.75 | $554.67 | -44.5% |
| 1 year ago | $2.89 | $719.72 | -28.0% |
| All time (5.0y) ago | $22.56 | $92.2 | -90.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GRCE forecast.
Our base-case forecast reaches $4.20 around 2033.
Implied market cap at $4.20: $68.35M
The forecast paints a bullish multi-year trajectory for GRCE. In 2026 the min price is $2.08, the avg is $2.08 and the max is $2.87, with a neutral sentiment and a 0 ROI pct. In 2027 the avg rises to $2.26, the min is $1.80, the max is $2.99, and the ROI is 8.4, remaining NEUTRAL.
From 2028 onward the path strengthens, with 2028 avg $2.57 and 2029 avg $2.75, and a continued bullish outlook through 2035 (avg values ranging from $3.16 in 2030 up to $4.58 in 2035) and a progressive rise in ROI (e.g., 2030 51.7, 2031 87.9, 2032 99.5, 2033 114.6, 2034 123.1, 2035 120.3).
The later years project even larger gains: 2040 avg $7.25 with a max of $12.18 and ROI 248.4, and 2050 avg $15.12 with a max of $27.79 and ROI 627. The sentiment remains BULLISH across these later years, reflecting a strong long-term upside scenario while acknowledging the higher levels of risk associated with a small-cap healthcare name and the inherent uncertainties of clinical-stage outcomes.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $3.16 with a 51.7 ROI (from the data), and a bullish sentiment.
The forecastTurn shows a shift to bullish sentiment from 2028 onward, with higher avg prices culminating in a 2050 avg of $15.12 and ROI of 627. However, these are estimates and not guarantees, and the stock remains a small-cap healthcare name.
Yes. The forecast max prices reach $12.18 in 2040 and $27.79 in 2050, indicating the potential for the price to exceed $10 in those years.
Current price is $2.08 and market cap is $33.85M.
RSI(14) is 30, sentiment is NEUTRAL, SMA50 is $2.35, SMA200 is $3.20. The 30-day range is $1.74 to $2.48, with support at $2.08 and resistance at $2.53.
Grace Therapeutics, Inc. Community Discussion
0Share your Grace Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.